Brokerages Set X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) PT at $8.50

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) has been assigned an average rating of “Hold” from the five ratings firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $8.50.

Several research analysts have weighed in on the stock. Weiss Ratings lowered shares of X4 Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 8th. Wall Street Zen upgraded shares of X4 Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. Finally, Guggenheim assumed coverage on shares of X4 Pharmaceuticals in a research note on Monday, March 9th. They issued a “buy” rating and a $12.00 price objective on the stock.

X4 Pharmaceuticals Stock Down 1.5%

Shares of NASDAQ:XFOR opened at $3.94 on Monday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 9.98 and a current ratio of 10.18. The company has a market cap of $371.62 million, a PE ratio of -0.87 and a beta of 0.31. X4 Pharmaceuticals has a 52 week low of $1.35 and a 52 week high of $4.83. The firm has a 50 day simple moving average of $4.14 and a 200 day simple moving average of $3.86.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.04. The business had revenue of $2.71 million during the quarter, compared to the consensus estimate of $3.20 million. X4 Pharmaceuticals had a negative net margin of 1,106.30% and a negative return on equity of 94.90%. As a group, research analysts expect that X4 Pharmaceuticals will post -0.77 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. SummitTX Capital L.P. acquired a new position in X4 Pharmaceuticals in the 1st quarter valued at approximately $46,000. Virtu Financial LLC acquired a new position in X4 Pharmaceuticals in the 4th quarter valued at approximately $90,000. Susquehanna Portfolio Strategies LLC acquired a new position in X4 Pharmaceuticals in the 4th quarter valued at approximately $173,000. Perceptive Advisors LLC acquired a new position in X4 Pharmaceuticals in the 4th quarter valued at approximately $25,258,000. Finally, Man Group plc acquired a new position in X4 Pharmaceuticals in the 4th quarter valued at approximately $97,000. Institutional investors and hedge funds own 72.03% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.